**DISCLAIMER- All products shown here are investigational and therefore limited information is available on the site.


About Us

Marizyme, Inc. is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes.

Investors, please visit our Investor section.

More About Marizyme



Our Products



DuraGraft®, is an investigational product used during Coronary Artery Bypass Grafting (CABG) surgery. DuraGraft is not yet approved in the US.

Learn More
group 4598



Our Pipeline Products / Technologies




Krillase-based MAR-VT-001®, a patent pending investigational product, based on extracts from Antarctic krill that contain proteolytic enzymes designed for veterinary dental indications to maintain dental health by reducing plaque and tartar. Krillase is not yet approved by the US FDA.

Learn More
group 1932


A patent-pending proprietary investigational device based on lab-on chip technology for point-of-care, CKD assessment. MATLOC is not yet approved in the US.

Learn More
group 103
group 98